Zoetis Inc (NYSE:ZTS) insider Roman Trawicki sold 8,568 shares of the business’s stock in a transaction on Friday, March 9th. The shares were sold at an average price of $83.10, for a total transaction of $712,000.80. Following the completion of the sale, the insider now directly owns 11,457 shares of the company’s stock, valued at $952,076.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Roman Trawicki also recently made the following trade(s):
- On Friday, February 23rd, Roman Trawicki sold 23,885 shares of Zoetis stock. The shares were sold at an average price of $82.00, for a total transaction of $1,958,570.00.
Shares of Zoetis Inc (NYSE:ZTS) traded down $0.11 during trading on Monday, hitting $84.41. 2,204,612 shares of the stock were exchanged, compared to its average volume of 2,922,079. Zoetis Inc has a twelve month low of $52.25 and a twelve month high of $85.05. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77. The firm has a market capitalization of $41,013.64, a price-to-earnings ratio of 48.23, a price-to-earnings-growth ratio of 1.90 and a beta of 0.97.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be paid a dividend of $0.126 per share. The ex-dividend date of this dividend is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. Zoetis’s dividend payout ratio (DPR) is 28.57%.
Several institutional investors have recently modified their holdings of ZTS. Raymond James Financial Services Advisors Inc. increased its stake in shares of Zoetis by 16.8% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 36,268 shares of the company’s stock worth $2,313,000 after acquiring an additional 5,227 shares during the period. Daiwa Securities Group Inc. grew its position in Zoetis by 8.6% during the third quarter. Daiwa Securities Group Inc. now owns 16,131 shares of the company’s stock worth $1,029,000 after buying an additional 1,281 shares during the period. Candriam Luxembourg S.C.A. grew its position in Zoetis by 8.4% during the third quarter. Candriam Luxembourg S.C.A. now owns 51,163 shares of the company’s stock worth $3,262,000 after buying an additional 3,943 shares during the period. Alps Advisors Inc. acquired a new position in Zoetis during the third quarter worth about $459,000. Finally, Global X MANAGEMENT CO LLC grew its position in Zoetis by 12.4% during the third quarter. Global X MANAGEMENT CO LLC now owns 11,618 shares of the company’s stock worth $741,000 after buying an additional 1,278 shares during the period. Institutional investors and hedge funds own 92.45% of the company’s stock.
ZTS has been the subject of a number of research reports. Cantor Fitzgerald set a $85.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Thursday, January 11th. Citigroup raised shares of Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 target price for the company in a report on Thursday, January 4th. Craig Hallum reaffirmed a “buy” rating and issued a $85.00 target price (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Cowen set a $80.00 target price on shares of Zoetis and gave the company a “buy” rating in a report on Friday, November 17th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $89.00 target price on shares of Zoetis in a report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the stock. Zoetis currently has an average rating of “Buy” and a consensus price target of $80.28.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.